Alcon Launches ILEVRO™ for Treatment of Pain and Inflammation Associated with Cataract Surgery

January 31, 2013

Last week, Alcon announced the launch of ILEVRO™ Suspension (nepafenac ophthalmic suspension 0.3%) as a once-daily treatment option for pain and inflammation associated with cataract surgery.

According to Alcon’s release, in two double masked, randomized clinical trials, ILEVRO™ Suspension demonstrated superior clinical efficacy compared to its vehicle; i.e., patients treated with ILEVRO™ Suspension were less likely to have ocular pain and measurable signs of inflammation (cells and flare) at the end of treatment than those treated with its vehicle.

Click here to read the full release on Alcon’s website.




Jump down to form below to submit your own comments

Comments are closed.